Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CardioGenics is planning to extend the commercialization process of CardioGenics' magnetic beads with Merck Chimie SAS.
Subscribe to our email newsletter
Merck will examine magentic beads coated with CardioGenics’ silver-coating and polymer encapsulation processes while refining encapsulation of the beads.
The silver-coating technology of the CardioGenics enhances the signaling properties of magnetic beads, resulting in an increased sensitivity of immunoassay analyzers by up to seven fold.
CardioGenics has also signed two material transfer agreements (MTA) with two international life sciences companies to advance magnetic beads commercialisation.
Under the second MTA, CardioGenics will furnish them with its silver-coated and polymer encapsulated magnetic beads for testing and evaluation in their various test products.
Following completion of the testing process, CardioGenics and the distributors will investigate the test results and determine whether to further pursue commercialization of the resulting products.